[1]
|
Ronco, P. and Debiec, H. (2015) Pathophysiological Advances in Membranous Nephropathy: Time for a Shift in Pa-tient’s Care. Lancet, 385, 1983-1992. https://doi.org/10.1016/S0140-6736(15)60731-0
|
[2]
|
Xu, X., Wang, G., Chen, N., et al. (2016) Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China. Journal of the American Society of Nephrology, 27, 3739-3746.
https://doi.org/10.1681/ASN.2016010093
|
[3]
|
刁宗礼, 郭增玉, 王华敏, 等. 2008-2020年北京市4 652例成人肾活检患者病理分析[J]. 中华全科医师杂志, 2021, 20(12): 1282-1287.
|
[4]
|
Polanco, N., Gutiérrez, E., Covarsí, A., et al. (2010) Spontaneous Remission of Nephrotic Syndrome in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology, 21, 697-704.
https://doi.org/10.1681/ASN.2009080861
|
[5]
|
Couser, W.G. (2017) Primary Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 12, 983-997. https://doi.org/10.2215/CJN.11761116
|
[6]
|
Hoxha, E., Harendza, S., Pinnschmidt, H., et al. (2014) PLA2R Antibody Levels and Clinical Outcome in Patients with Mem-branous Nephropathy and Non-Nephrotic Range Proteinuria under Treatment with Inhibitors of the Renin-Angiotensin System. PLOS ONE, 9, e110681. https://doi.org/10.1371/journal.pone.0110681
|
[7]
|
Ruggenenti, P., Debiec, H., Ruggiero, B., et al. (2015) Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Mem-branous Nephropathy. Journal of the American Society of Nephrology, 26, 2545-2558.
https://doi.org/10.1681/ASN.2014070640
|
[8]
|
Ferro, C.J., Mark, P.B., Kanbay, M., et al. (2018) Lipid Manage-ment in Patients with Chronic Kidney Disease. Nature Reviews Nephrology, 14, 727-749. https://doi.org/10.1038/s41581-018-0072-9
|
[9]
|
Nishi, S., Ubara, Y., Utsunomiya, Y., et al. (2016) Evi-dence-Based Clinical Practice Guidelines for Nephrotic Syndrome 2014. Clinical and Experimental Nephrology, 20, 342-370. https://doi.org/10.1007/s10157-015-1216-x
|
[10]
|
Shiiki, H., Saito, T., Nishitani, Y., et al. (2004) PProg-nosis and Risk Factors for Idiopathic Membranous Nephropathy with Nephrotic Syndrome in Japan. Kidney Internation-al, 65, 1400-1407.
https://doi.org/10.1111/j.1523-1755.2004.00518.x
|
[11]
|
Tang, S., Chan, T.M., Cheng, I.K.P. and Lai, K.N. (1999) Clinical Features and Treatment Outcome of Idiopathic Membranous Nephropathy in Chinese Patients. QJM: An Interna-tional Journal of Medicine, 92, 401-406.
https://doi.org/10.1093/qjmed/92.7.401
|
[12]
|
Shin, D.H., Lee, M.J., Oh, H.J., et al. (2013) Stepwise Treatment Us-ing Corticosteroids Alone and in Combination with Cyclosporine in Korean Patients with Idiopathic Membranous Nephropathy. Yonsei Medical Journal, 54, 973-982.
https://doi.org/10.3349/ymj.2013.54.4.973
|
[13]
|
Ponticelli, C., Zucchelli, P., Passerini, P., et al. (1995) A 10-Year Follow-up of a Randomized Study with Methylprednisolone and Chlorambucil in Membranous Nephropathy. Kidney In-ternational, 48, 1600-1604.
https://doi.org/10.1038/ki.1995.453
|
[14]
|
Du Buf-Vereijken, P.W.G., Branten, A.J.W. and Wetzels, J.F.M. (2005) Idiopathic Membranous Nephropathy: Outline and Rationale of a Treatment Strategy. American Journal of Kidney Dis-eases, 46, 1012-1029.
https://doi.org/10.1053/j.ajkd.2005.08.020
|
[15]
|
Beck, L., Bomback, A.S., Choi, M.J., et al. (2013) KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis. American Journal of Kidney Dis-eases, 62, 403-441.
https://doi.org/10.1053/j.ajkd.2013.06.002
|
[16]
|
Floege, J., Barbour, S.J., Cattran, D.C., et al. (2019) Management and Treatment of Glomerular Diseases (Part 1): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 95, 268-280. https://doi.org/10.1016/j.kint.2018.10.018
|
[17]
|
Jha, V., Ganguli, A., Saha, T.K., et al. (2007) A Randomized, Con-trolled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology, 18, 1899-1904. https://doi.org/10.1681/ASN.2007020166
|
[18]
|
van den Brand, J.A., van Dijk, P.R., Hofstra, J.M. and Wetzels, J.F. (2014) Long-Term Outcomes in Idiopathic Membranous Nephropathy Using a Restrictive Treatment Strategy. Journal of the American Society of Nephrology, 25, 150-158. https://doi.org/10.1681/ASN.2013020185
|
[19]
|
Radhakrishnan, J. and Cattran, D.C. (2012) The KDIGO Practice Guideline on Glomerulonephritis: Reading between the (Guide)Lines—Application to the Individual Patient. Kidney International, 82, 840-856.
https://doi.org/10.1038/ki.2012.280
|
[20]
|
Howman, A., Chapman, T.L., Langdon, M.M., et al. (2013) Immunosup-pression for Progressive Membranous Nephropathy: A UK Randomised Controlled Trial. Lancet, 381, 744-751. https://doi.org/10.1016/S0140-6736(12)61566-9
|
[21]
|
Lin, S., Li, H.Y., Zhou, T. and Lin, W. (2019) Efficacy and Safety of Cyclosporine A in the Treatment of Idiopathic Membranous Nephropathy in an Asian Population. Drug Design, Development and Therapy, 13, 2305-2330.
https://doi.org/10.2147/DDDT.S204974
|
[22]
|
陈忠锋, 张建伟, 夏楠楠, 何兵. 环孢素A与环磷酰胺联合激素治疗特发性膜性肾病的疗效比较[J]. 中国医药科学, 2014, 4(16): 16-18+60.
|
[23]
|
Kim, Y., Yoon, H.E., Chung, B.H., et al. (2019) Clinical Outcomes and Effects of Treatment in Older Patients with Idiopathic Membranous Nephrop-athy. The Korean Journal of Internal Medicine, 34, 1091-1099.
https://doi.org/10.3904/kjim.2018.139
|
[24]
|
Alexopoulos, E., Papagianni, A., Tsamelashvili, M., Leontsini, M. and Memmos, D. (2006) Induction and Long-Term Treatment with Cyclosporine in Membranous Nephropathy with the Ne-phrotic Syndrome. Nephrology Dialysis Transplantation, 21, 3127-3132. https://doi.org/10.1093/ndt/gfl360
|
[25]
|
李忠心, 陈向东, 李新. 小剂量环孢素A联合小剂量激素治疗原发性肾病综合征疗效观察[J]. 中华临床医师杂志(电子版), 2013, 7(7): 2870-2873.
|
[26]
|
Li, J., Zhang, Y.-M., Qu, Z., Zhao, M.-H. and Liu, G. (2010) Low-Dose Cy-closporine Treatment in Chinese Nephrotic Patients with Idiopathic Membranous Nephropathy: An Uncontrolled Study with Prospective Follow-up. The American Journal of the Medical Sciences, 339, 532-536. https://doi.org/10.1097/MAJ.0b013e3181d9f00b
|
[27]
|
王维. 不同剂量激素联合环孢素(CSA)治疗特发性膜性肾病(IMn)的疗效及不良反应分析[J]. 中外女性健康研究, 2018(16): 45+53.
|
[28]
|
Jurewicz, W.A. (2003) Tacroli-mus versus Cyclosporin Immunosuppression: Long-Term Outcome in Renal Transplantation. Nephrology Dialysis Transplantation, 18, i7-i11. https://doi.org/10.1093/ndt/gfg1028
|
[29]
|
Praga, M., Barrio, V., Fernández Juárez, G. and Luño, J. (2007) Tacrolimus Monotherapy in Membranous Nephropathy: A Randomized Controlled Trial. Kidney In-ternational, 71, 924-930. https://doi.org/10.1038/sj.ki.5002215
|
[30]
|
Zou, H., Jiang, F. and Xu, G. (2019) Effec-tiveness and Safety of Cyclophosphamide or Tacrolimus Therapy for Idiopathic Membranous Nephropathy. Renal Fail-ure, 41, 673-681. https://doi.org/10.1080/0886022X.2019.1637758
|
[31]
|
Zhu, L.-B., Liu, L.-L., Yao, L. and Wang, L.-N. (2017) Efficacy and Safety of Tacrolimus versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis. Drugs, 77, 187-199.
https://doi.org/10.1007/s40265-016-0683-z
|
[32]
|
Yuan, H., Liu, N., Sun, G.-D., et al. (2013) Effect of Prolonged Tacrolimus Treatment in Idiopathic Membranous Nephropathy with Nephrotic Syndrome. Pharmacology, 91, 259-266. https://doi.org/10.1159/000348570
|
[33]
|
Chan, T.M., Li, F.K., Tang, C.S., et al. (2000) Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis. New England Journal of Medicine, 343, 1156-1162. https://doi.org/10.1056/NEJM200010193431604
|
[34]
|
Miller, G., Zimmerman 3rd., R., Radhakrishnan, J. and Ap-pel, G. (2000) Use of Mycophenolate Mofetil in Resistant Membranous Nephropathy. American Journal of Kidney Dis-eases, 36, 250-256.
https://doi.org/10.1053/ajkd.2000.8968
|
[35]
|
Dussol, B., Morange, S., Burtey, S., et al. (2008) Mycophenolate Mofetil Monotherapy in Membranous Nephropathy: A 1-Year Randomized Controlled Trial. American Journal of Kid-ney Diseases, 52, 699-705.
https://doi.org/10.1053/j.ajkd.2008.04.013
|
[36]
|
Chan, T.M., Lin, A.W., Tang, S.C., et al. (2007) Prospective Con-trolled Study on Mycophenolate Mofetil and Prednisolone in the Treatment of Membranous Nephropathy with Nephrotic Syndrome. Nephrology, 12, 576-581.
https://doi.org/10.1111/j.1440-1797.2007.00822.x
|
[37]
|
Xie, G., Xu, J., Ye, C., et al. (2012) Immunosuppressive Treatment for Nephrotic Idiopathic Membranous Nephropathy: A Meta-Analysis Based on Chinese Adults. PLOS ONE, 7, e44330. https://doi.org/10.1371/journal.pone.0044330
|
[38]
|
Choi, J.-Y., Kim, D.-K., Kim, Y.-W., et al. (2018) The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: A Multicenter Randomized Trial. Journal of Korean Med-ical Science, 33, e74. https://doi.org/10.3346/jkms.2018.33.e74
|
[39]
|
Van De Logt, A.-E., Hofstra, J.M. and Wet-zels, J.F. (2019) Pharmacological Treatment of Primary Membranous Nephropathy in 2016. Expert Review of Clinical Pharmacology, 9, 1463-1478.
https://doi.org/10.1080/17512433.2016.1225497
|
[40]
|
Berg, A.-L., Nilsson-Ehle, P. and Arnadottir, M. (1999) Beneficial Effects of ACTH on the Serum Lipoprotein Profile and Glomerular Function in Patients with Membranous Nephropathy. Kidney International, 56, 1534-1543.
https://doi.org/10.1046/j.1523-1755.1999.00675.x
|
[41]
|
Ponticelli, C., Passerini, P., Salvadori, M., et al. (2006) A Randomized Pilot Trial Comparing Methylprednisolone Plus a Cytotoxic Agent versus Synthetic Adrenocorticotropic Hormone in Idiopathic Membranous Nephropathy. American Journal of Kidney Diseases, 47, 233-240. https://doi.org/10.1053/j.ajkd.2005.10.016
|
[42]
|
Van De Logt, A.-E., Beerenhout, C.-H., Brink, H.S., et al. (2015) Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study. PLOS ONE, 10, e0142033.
https://doi.org/10.1371/journal.pone.0142033
|
[43]
|
Hladunewich, M.A., Cattran, D., Beck, L.H., et al. (2014) A Pilot Study to Determine the Dose and Effectiveness of Adrenocorticotrophic Hormone (H.P. Acthar® Gel) in Nephrotic Syndrome due to Idiopathic Membranous Nephropathy. Nephrology Dialysis Transplantation, 29, 1570-1577. https://doi.org/10.1093/ndt/gfu069
|
[44]
|
Gauckler, P., Shin, J.I., Alberici, F., et al. (2021) Rituximab in Membra-nous Nephropathy. Kidney International Reports, 6, 881-893. https://doi.org/10.1016/j.ekir.2020.12.035
|
[45]
|
Dahan, K., Debiec, H., Plaisier, E., et al. (2016) Rituximab for Se-vere Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. Journal of the American Society of Neph-rology, 28, 348-358.
https://doi.org/10.1681/ASN.2016040449
|
[46]
|
Fervenza, F.C., Appel, G.B., Barbour, S.J, et al. (2019) Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. New England Journal of Medicine, 381, 36-46. https://doi.org/10.1056/NEJMoa1814427
|
[47]
|
Waldman, M., Beck Jr., L.H., Braun, M., et al. (2016) Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab. Kidney International Reports, 1, 73-84.
https://doi.org/10.1016/j.ekir.2016.05.002
|
[48]
|
Wang, X., Cui, Z., Zhang, Y. M., et al. (2018) Rituximab for Non-Responsive Idiopathic Membranous Nephropathy in a Chinese Cohort. Nephrology Dialysis Transplantation, 33, 1558-1563.
|
[49]
|
Scolari, F., Delbarba, E., Santoro, D., et al. (2021) Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. Journal of the American Society of Nephrology, 32, 972-982.
https://doi.org/10.1681/ASN.2020071091
|
[50]
|
Van Den Brand, J., Ruggenenti, P., Chianca, A., et al. (2027) Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology, 28, 2729-2737.
https://doi.org/10.1681/ASN.2016091022
|
[51]
|
Podestà, M.A., Ruggiero, B., Remuzzi, G. and Ruggenenti, P. (2020) Ofatumumab for Multirelapsing Membranous Nephropathy Complicated by Rituximab-Induced Serum-Sickness. BMJ Case Reports, 13, e232896.
https://doi.org/10.1136/bcr-2019-232896
|
[52]
|
Podestà, M.A., Gennarini, A., Portalupi, V., et al. (2020) Accelerat-ing the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab. Nephron, 144, 30-35. https://doi.org/10.1159/000501858
|
[53]
|
Boyer-Suavet, S., Andreani, M., Lateb, M., et al. (2019) Neutralizing An-ti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated with Rituximab. Frontiers in Immunology, 10, Article 3069.
https://doi.org/10.3389/fimmu.2019.03069
|
[54]
|
Sethi, S., Kumar, S., Lim, K. and Jordan, S.C. (2020) Obinutuzumab Is Effective for the Treatment of Refractory Membranous Nephropathy. Kidney International Reports, 5, 1515-1518. https://doi.org/10.1016/j.ekir.2020.06.030
|
[55]
|
Klomjit, N., Fervenza, F.C. and Zand, L. (2020) Suc-cessful Treatment of Patients with Refractory PLA2R-Associated Membranous Nephropathy with Obinutuzumab: A Re-port of 3 Cases. American Journal of Kidney Diseases, 76, 883-888.
https://doi.org/10.1053/j.ajkd.2020.02.444
|
[56]
|
Barrett, C., Willcocks, L.C., Jones, R.B., et al. (2020) Effect of Belimumab on Proteinuria and Anti-Phospholipase A2 Receptor Autoantibody in Primary Membranous Nephropathy. Nephrology Dialysis Transplantation, 35, 599-606.
https://doi.org/10.1093/ndt/gfz086
|
[57]
|
Schmidt, T., Schulze, M., Harendza, S. and Hoxha, E. (2021) Successful Treatment of PLA2R1-Antibody Positive Membranous Nephropathy with Ocrelizumab. Journal of Nephrology, 34, 603-606.
https://doi.org/10.1007/s40620-020-00874-2
|